Durvalumab Plus Tremelimumab for Frontline, Metastatic, Urothelial Cancer, The Phase III DANUBE Trial - Thomas Powles

October 6, 2020

The DANUBE study was designed as a randomized phase 3 study to investigate durvalumab monotherapy versus durvalumab + tremelimumab versus platinum-based chemotherapy in the first-line setting for patients with unresectable, locally advanced, or metastatic urothelial carcinoma. In this conversation with Alicia Morgans, MD, MPH, Thomas Powles, MD shares results of the phase 3 DANUBE study presented at the 2020 ESMO annual congress. The DANUBE trial was negative for its co-primary endpoints of overall survival yet results from the secondary endpoint analysis of combination immunotherapy in the PD-L1 high population warrants further investigation. Given the longer duration of response with immunotherapy, identification of which patients are likely to benefit from immunotherapy remains a critical question for investigation moving forward.

Biographies:

Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead for Solid Tumour Research at Barts Cancer Institute, Director of Barts Cancer Institute, London, United Kingdom

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.